Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study

Breast Cancer Research and Treatment
Mark O'LoughlinGrace Callagy

Abstract

Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance being achievable using a software tool. We examined agreement between breast pathologists across Europe scoring sTILs on H&E-stained sections without software, an approach that is easily applied in clinical practice. The association between sTILs and response to anthracycline-taxane NACT was also examined. Pathologists from the European Working Group for Breast Screening Pathology scored sTILs in 84 slides from 75 TNBCs using the immune-oncology biomarker working group guidance in two circulations. There were 16 participants in the first and 19 in the second circulation. Moderate agreement was achieved for absolute sTILs scores (intraclass correlation coefficient (ICC) = 0.683, 95% CI 0.601-0.767, p-value < 0.001). Agreement was less when a 25% threshold was used (ICC 0.509, 95% CI 0.416-0.614, p-value < 0.001) and for lymphocyte predominant breast cancer (LPBC) (ICC 0.504, 95% CI 0.412-0.610, p-value < 0.001). Intra-observer agreement was strong for absolute sTIL values (Spearman ρ = 0.727); fair f...Continue Reading

References

Jun 1, 1986·Journal of Clinical Pathology·J R Jass
Nov 14, 1997·International Journal of Cancer. Journal International Du Cancer·A J MarrogiS M Freeman
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Padmanee SharmaEiichi Sato
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertGunter von Minckwitz
Mar 17, 2012·Breast Cancer Research : BCR·Shuzhen LiuTorsten O Nielsen
Jul 27, 2012·Tutorials in Quantitative Methods for Psychology·Kevin A Hallgren
Jan 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre
Jun 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H R AliC Caldas
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvia AdamsSunil S Badve
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertSibylle Loibl
May 23, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciA Goubar
Sep 9, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A I Hida, Y Ohi
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G PruneriG Viale
Jul 2, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Carsten DenkertRoberto Salgado
Apr 20, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wendy A CooperStephen B Fox
Jul 6, 2017·The Lancet Oncology·Brian O'SullivanMary Gospodarowicz
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre

❮ Previous
Next ❯

Citations

Jul 2, 2020·OncoTargets and Therapy·Weilin XuJinhai Tang
Dec 28, 2019·Breast Cancer Research : BCR·Iris NederlofChristine Desmedt
Jul 19, 2020·Pathology Oncology Research : POR·Hulya Sahin OzkanHandan Kaya
May 3, 2019·Cancer Research·Rachel L StewartKatherine E Varley
Sep 29, 2020·Annals of Diagnostic Pathology·Mieke R Van BockstalChristine Galant
May 14, 2021·Breast Cancer Research and Treatment·A J EustaceB T Hennessy
Jul 5, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Mieke R Van BockstalChristine Galant
Aug 15, 2021·Journal for Immunotherapy of Cancer·Leisha A EmensJennifer K Litton
Aug 11, 2020·Breast Care·Mercedes Herrera JuarezEva Ciruelos Gil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.